Evidence mapPaperPMID 33472172Full record

Trial reportAging2021

Anserine, HClO-scavenger, protected against cognitive decline in individuals with mild cognitive impairment.

Nobutaka Masuoka, Chenxu Lei, Haowei Li, Noriko Inamura, Shigenobu Shiotani, Nobuya Yanai, Kenichiro Sato, Keisuke Sakurai, Tatsuhiro Hisatsune

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Aging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Nobutaka MasuokaGraduate School of Frontier Sciences, The University of Tokyo, Kashiwa, Japan.
Chenxu LeiGraduate School of Frontier Sciences, The University of Tokyo, Kashiwa, Japan.
Haowei LiGraduate School of Frontier Sciences, The University of Tokyo, Kashiwa, Japan.
Noriko InamuraCommunity Hearth Promotion Laboratory, Mitsui Fudosan, Co., Ltd., Kashiwa, Japan.
Shigenobu ShiotaniResearch Division, Tokai Bussan Co., Ltd., Tokyo, Japan.
Nobuya YanaiResearch Division, Tokai Bussan Co., Ltd., Tokyo, Japan.
Kenichiro SatoResearch Division, Tokai Bussan Co., Ltd., Tokyo, Japan.
Keisuke SakuraiGraduate School of Frontier Sciences, The University of Tokyo, Kashiwa, Japan.
Tatsuhiro HisatsuneGraduate School of Frontier Sciences, The University of Tokyo, Kashiwa, Japan.
The University of Tokyo · JPMitsui (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neuroinflammation has been recognized as a promising target when considering strategies for treating AD. In particular, it has been shown that neutrophils and MPO-mediated neuroinflammatory responses with the production of HClO play a role in the progression of AD. In this study, we aimed to evaluate the effects of anserine, a scavenger of HClO, on the protection of cognitive declines in persons with MCI. Fifty-eight elderly volunteers were screened, and 36 MCI individuals were assigned either to an active arm, who received 500 mg anserine per day, or a placebo arm, for 12-weeks. To assess cognitive function, we performed MMSE at baseline and after the ingestion. The data of the MMSE for 30 subjects who completed the follow-up tests were analyzed. A significant difference was detected in the change score of MMSE between the active arm (1.9 ± 2.0; n = 15) and the placebo arm (0 ± 2.8; n = 15) (

Indexed as

AgedAnserineAntioxidantsCognitionCognitive DysfunctionDisease ProgressionDouble-Blind MethodFemaleHumansMaleNeuropsychological TestsAnserineAntioxidantsAlzheimer’s diseaseanserinehypochlorous acidmild cognitive impairmentmyeloperoxidase

Identifiers

PMID33472172
PMCPMC7880346
OpenAlexW3121435312

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.